Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Dianthus Therapeutics, Inc. /DE/MGTA · Entity 1813 | See Remarks | February 11, 2021 | February 16, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Dianthus Therapeutics, Inc. /DE/
Report date February 11, 2021 · Filed February 16, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.80 · Expires 2031-02-10 | Direct | 72,500 |
Reported balance
After 2021-02-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-02-11 · Grant · Acquired 72,500 · Balance 72,500 F1: This option shall vest and become exercisable in 16 equal quarterly installments beginning on January 1, 2021. |
Filing footnotes · ownership attribution and instrument terms
F1: This option shall vest and become exercisable in 16 equal quarterly installments beginning on January 1, 2021.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 11, 2021 Filed Feb 16, 2021 22:48 UTC | Dianthus Therapeutics, Inc. /DE/ MGTA · Entity 1813 | GrantStock Option (Right to Buy) · Derivative | 72,500 | $0.00 Strike: $10.80 | $0.00 |
DisclosureSEC source: 0000899243-21-006715 · doc4.xml · derivative · entry 1 DAVIS JOHN C. JR · CIK 0001741287 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,500 Underlying: Common Stock · 72,500 shares Expires 2031-02-10 F1 · derivative.exercise_date: This option shall vest and become exercisable in 16 equal quarterly installments beginning on January 1, 2021. Read SEC document |
| April 14, 2020 Filed Apr 16, 2020 20:52 UTC | Dianthus Therapeutics, Inc. /DE/ MGTA · Entity 1813 | GrantStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $8.18 | $0.00 |
DisclosureSEC source: 0000899243-20-010847 · doc4.xml · derivative · entry 1 DAVIS JOHN C. JR · CIK 0001741287 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2030-04-13 F1 · derivative.exercise_date: This option shall vest and become exercisable in 16 equal quarterly installments beginning on April 14, 2020. Read SEC document |
| February 10, 2020 Filed Feb 12, 2020 22:19 UTC | Dianthus Therapeutics, Inc. /DE/ MGTA · Entity 1813 | GrantStock Option (Right to Buy) · Derivative | 104,000 | $0.00 Strike: $12.28 | $0.00 |
DisclosureSEC source: 0000899243-20-004321 · doc4.xml · derivative · entry 1 DAVIS JOHN C. JR · CIK 0001741287 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,000 Underlying: Common Stock · 104,000 shares Expires 2030-02-09 F1 · derivative.exercise_date: This option shall vest and become exercisable in 16 equal quarterly installments beginning on January 1, 2020. Read SEC document |
| January 02, 2020 Filed Jan 3, 2020 21:01 UTC | Dianthus Therapeutics, Inc. /DE/ MGTA · Entity 1813 | Exercise / conversionStock Option (Right to Buy) · Derivative | 11,294 | $0.00 Strike: $9.49 | $0.00 |
DisclosureSEC source: 0001562180-20-000119 · primarydocument.xml · derivative · entry 3 DAVIS JOHN C. JR · CIK 0001741287 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 224,831 Underlying: Common Stock · 11,294 shares Expires 2028-04-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 25% vested on February 16, 2019 with the remaining 75% vesting in 12 equal quarterly installments thereafter. Read SEC document |
| January 02, 2020 Filed Jan 3, 2020 21:01 UTC | Dianthus Therapeutics, Inc. /DE/ MGTA · Entity 1813 | SaleCommon Stock | 11,294 | $15.04 | $169,816.58 |
DisclosureSEC source: 0001562180-20-000119 · primarydocument.xml · nonDerivative · entry 2 DAVIS JOHN C. JR · CIK 0001741287 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,304 F1 · kind: This trade is pursuant to an active 10b5-1 plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $15.00 to $15.09. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request by the staff of the U.S. Securities and Exchange Commission, the issuer or a security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 02, 2020 Filed Jan 3, 2020 21:01 UTC | Dianthus Therapeutics, Inc. /DE/ MGTA · Entity 1813 | Exercise / conversionCommon Stock | 11,294 | $9.49 | $107,180.06 |
DisclosureSEC source: 0001562180-20-000119 · primarydocument.xml · nonDerivative · entry 1 DAVIS JOHN C. JR · CIK 0001741287 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,598 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 20, 2019 Filed Dec 20, 2019 22:52 UTC | Dianthus Therapeutics, Inc. /DE/ MGTA · Entity 1813 | Exercise / conversionStock Option (Right to Buy) · Derivative | 114 | $0.00 Strike: $9.49 | $0.00 |
DisclosureSEC source: 0001562180-19-006220 · primarydocument.xml · derivative · entry 5 DAVIS JOHN C. JR · CIK 0001741287 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 236,125 Underlying: Common Stock · 114 shares Expires 2028-04-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 25% vested on February 16, 2019 with the remaining 75% vesting in 12 equal quarterly installments thereafter. Read SEC document |
| December 20, 2019 Filed Dec 20, 2019 22:52 UTC | Dianthus Therapeutics, Inc. /DE/ MGTA · Entity 1813 | Exercise / conversionStock Option (Right to Buy) · Derivative | 805 | $0.00 Strike: $9.49 | $0.00 |
DisclosureSEC source: 0001562180-19-006220 · primarydocument.xml · derivative · entry 4 DAVIS JOHN C. JR · CIK 0001741287 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 236,239 Underlying: Common Stock · 805 shares Expires 2028-04-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 25% vested on February 16, 2019 with the remaining 75% vesting in 12 equal quarterly installments thereafter. Read SEC document |
| December 20, 2019 Filed Dec 20, 2019 22:52 UTC | Dianthus Therapeutics, Inc. /DE/ MGTA · Entity 1813 | SaleCommon Stock | 919 | $15.00 | $13,785.00 |
DisclosureSEC source: 0001562180-19-006220 · primarydocument.xml · nonDerivative · entry 3 DAVIS JOHN C. JR · CIK 0001741287 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,304 F1 · kind: This trade is pursuant to an active 10b5-1 plan. Read SEC document |
| December 20, 2019 Filed Dec 20, 2019 22:52 UTC | Dianthus Therapeutics, Inc. /DE/ MGTA · Entity 1813 | Exercise / conversionCommon Stock | 805 | $9.49 | $7,639.45 |
DisclosureSEC source: 0001562180-19-006220 · primarydocument.xml · nonDerivative · entry 2 DAVIS JOHN C. JR · CIK 0001741287 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,223 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 20, 2019 Filed Dec 20, 2019 22:52 UTC | Dianthus Therapeutics, Inc. /DE/ MGTA · Entity 1813 | Exercise / conversionCommon Stock | 114 | $9.49 | $1,081.86 |
DisclosureSEC source: 0001562180-19-006220 · primarydocument.xml · nonDerivative · entry 1 DAVIS JOHN C. JR · CIK 0001741287 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,418 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 10, 2019 Filed Dec 11, 2019 21:03 UTC | Dianthus Therapeutics, Inc. /DE/ MGTA · Entity 1813 | Exercise / conversionStock Option (Right to Buy) · Derivative | 17,055 | $0.00 Strike: $9.49 | $0.00 |
DisclosureSEC source: 0001562180-19-006009 · primarydocument.xml · derivative · entry 6 DAVIS JOHN C. JR · CIK 0001741287 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 237,044 Underlying: Common Stock · 17,055 shares Expires 2028-04-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 25% vested on February 16, 2019 with the remaining 75% vesting in 12 equal quarterly installments thereafter. Read SEC document |
| December 10, 2019 Filed Dec 11, 2019 21:03 UTC | Dianthus Therapeutics, Inc. /DE/ MGTA · Entity 1813 | SaleCommon Stock | 17,055 | $15.00 | $255,825.00 |
DisclosureSEC source: 0001562180-19-006009 · primarydocument.xml · nonDerivative · entry 4 DAVIS JOHN C. JR · CIK 0001741287 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,304 F1 · kind: This trade is pursuant to an active 10b5-1 plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $15.00 to $15.10. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request by the staff of the U.S. Securities and Exchange Commission, the issuer or a security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 10, 2019 Filed Dec 11, 2019 21:03 UTC | Dianthus Therapeutics, Inc. /DE/ MGTA · Entity 1813 | Exercise / conversionCommon Stock | 17,055 | $9.49 | $161,851.95 |
DisclosureSEC source: 0001562180-19-006009 · primarydocument.xml · nonDerivative · entry 3 DAVIS JOHN C. JR · CIK 0001741287 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,359 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 09, 2019 Filed Dec 11, 2019 21:03 UTC | Dianthus Therapeutics, Inc. /DE/ MGTA · Entity 1813 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,614 | $0.00 Strike: $9.49 | $0.00 |
DisclosureSEC source: 0001562180-19-006009 · primarydocument.xml · derivative · entry 5 DAVIS JOHN C. JR · CIK 0001741287 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 254,099 Underlying: Common Stock · 4,614 shares Expires 2028-04-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 25% vested on February 16, 2019 with the remaining 75% vesting in 12 equal quarterly installments thereafter. Read SEC document |
| December 09, 2019 Filed Dec 11, 2019 21:03 UTC | Dianthus Therapeutics, Inc. /DE/ MGTA · Entity 1813 | SaleCommon Stock | 4,614 | $15.00 | $69,210.00 |
DisclosureSEC source: 0001562180-19-006009 · primarydocument.xml · nonDerivative · entry 2 DAVIS JOHN C. JR · CIK 0001741287 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,304 F1 · kind: This trade is pursuant to an active 10b5-1 plan. Read SEC document |
| December 09, 2019 Filed Dec 11, 2019 21:03 UTC | Dianthus Therapeutics, Inc. /DE/ MGTA · Entity 1813 | Exercise / conversionCommon Stock | 4,614 | $9.49 | $43,786.86 |
DisclosureSEC source: 0001562180-19-006009 · primarydocument.xml · nonDerivative · entry 1 DAVIS JOHN C. JR · CIK 0001741287 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,918 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 05, 2019 Filed Feb 7, 2019 21:20 UTC | Dianthus Therapeutics, Inc. /DE/ MGTA · Entity 1813 | GrantStock Option (Right to Buy) · Derivative | 70,000 | $0.00 Strike: $7.13 | $0.00 |
DisclosureSEC source: 0000899243-19-002872 · doc4.xml · derivative · entry 1 DAVIS JOHN C. JR · CIK 0001741287 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Stock · 70,000 shares Expires 2029-02-04 F1 · derivative.exercise_date: This option shall vest and become exercisable in 12 equal quarterly installments beginning on January 1, 2019. Read SEC document |
| June 25, 2018 Filed Jun 27, 2018 20:24 UTC | Dianthus Therapeutics, Inc. /DE/ MGTA · Entity 1813 | ConversionSeries C Preferred Stock · Derivative | 21,459 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-18-018317 · doc4.xml · derivative · entry 2 DAVIS JOHN C. JR · CIK 0001741287 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,304 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Series C Preferred Stock converted into Common Stock on a 2.58398:1 basis upon the closing of the Issuer's initial public offering on June 25, 2018. The Series C Preferred Stock had no expiration date. F1 · price: The Series C Preferred Stock converted into Common Stock on a 2.58398:1 basis upon the closing of the Issuer's initial public offering on June 25, 2018. The Series C Preferred Stock had no expiration date. F1 · derivative.exercise_date: The Series C Preferred Stock converted into Common Stock on a 2.58398:1 basis upon the closing of the Issuer's initial public offering on June 25, 2018. The Series C Preferred Stock had no expiration date. F1 · derivative.expiration_date: The Series C Preferred Stock converted into Common Stock on a 2.58398:1 basis upon the closing of the Issuer's initial public offering on June 25, 2018. The Series C Preferred Stock had no expiration date. Read SEC document |
| June 25, 2018 Filed Jun 27, 2018 20:24 UTC | Dianthus Therapeutics, Inc. /DE/ MGTA · Entity 1813 | ConversionCommon Stock | 8,304 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-18-018317 · doc4.xml · nonDerivative · entry 1 DAVIS JOHN C. JR · CIK 0001741287 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,304 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Series C Preferred Stock converted into Common Stock on a 2.58398:1 basis upon the closing of the Issuer's initial public offering on June 25, 2018. The Series C Preferred Stock had no expiration date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.